- Dutch biotech uniQure N.V. (QURE) reports Q1 results. License and collaboration revenues: EURO1.2M; R&D expenses: EURO6.2M (+72.2%); net loss: EURO7.8M (-50.0%); loss/share: EURO0.52 (+1.9%); cash and equivalents: EURO77.5M. Increase in R&D expenses was due to the expansion of activities in the hemophilia B program.
- Signed a strategic collaboration with 4D Molecular Therapeutics for exclusive access to 4D's adeno-associated viral (AAV) vector discovery and optimization technology for gene delivery to the central nervous system and liver.
- Commercialization partner Chiesi advanced the launch of Glybera by establishing centers of excellence and working on reimbursement issues.
- Hemophilia B AAV5 candidate Phase 1/2 trial expected to start by the end of the year.
Check out Seeking Alpha’s new Earnings Center »
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs